Halpenny M, Markos F, Snow H M, Duggan P F, Gaffney E, O'Connell D P, Shorten G D
Department of Anesthesia and Intensive Care Medicine, Mercy Hospital and University College Cork, Wilton, Cork, Ireland.
Crit Care Med. 2001 Apr;29(4):855-60. doi: 10.1097/00003246-200104000-00034.
It was hypothesized that fenoldopam mesylate, a selective dopamine agonist, may preserve renal perfusion and decrease tubular oxygen consumption during states of hypoperfusion, such as hypovolemic shock. The objective of this study was to quantify the effects of fenoldopam (0.1 microg x kg(-1) x min(-1)) on renal blood flow, urine output, creatinine clearance, and sodium clearance in pentobarbital anesthetized dogs that had undergone partial exsanguination to acutely decrease cardiac output.
Prospective, randomized, controlled experiment.
University-based animal laboratory and research unit.
Eight female beagle dogs.
Arterial blood pressure, heart rate, cardiac output, renal blood flow, urine output, creatinine clearance, and fractional excretion of sodium were measured and calculated at four times: a) before infusion of fenoldopam or normal saline; b) during infusion of fenoldopam or normal saline (1 hr); c) during a 90-min period of hypovolemia (induced by acute partial exsanguination), with concurrent infusion of fenoldopam or normal saline; and d) during a 1-hr period after retransfusing the dogs.
Administration of fenoldopam (0.1 microg x kg(-1) x min(-1)) was not associated with hemodynamic instability. Renal blood flow and urine output decreased significantly from baseline (p <.01) during the hypovolemic period in the placebo group (72 +/- 20 to 47 +/- 6 mL/min and 0.26 +/- 0.15 to 0.08 +/- 0.05 mL/min, respectively) but not in the fenoldopam group (75 +/- 14 to 73 +/- 17 mL/min and 0.3 +/- 0.19 to 0.14 +/- 0.05 mL/min, respectively). Creatinine clearance and fractional excretion of sodium decreased significantly from baseline (p <.01) in the placebo group during the hypovolemic period (3.0 +/- 0.4 to 1.8 +/- 0.8 mL x kg(-1) x min(-1) and 1.7% +/- 0.9% to 0.4% +/- 0.2%, respectively) but not in the dogs that received fenoldopam (3.0 +/- 1.0 to 2.9 +/- 0.5 mL x kg(-1) x min(-1) and 1.9% +/- 1.1% to 1.7% +/- 2.7%, respectively).
Fenoldopam ablated the tubular prerenal response to profound hypovolemia and maintained renal blood flow, glomerular filtration rate, and natriuresis without causing hypotension. This suggests that fenoldopam may have a renoprotective effect in acute ischemic injury.
有假设认为,甲磺酸非诺多泮(一种选择性多巴胺激动剂)在诸如低血容量性休克等低灌注状态下可能会维持肾灌注并降低肾小管耗氧量。本研究的目的是量化非诺多泮(0.1微克/千克/分钟)对经部分放血以急性降低心输出量的戊巴比妥麻醉犬的肾血流量、尿量、肌酐清除率和钠清除率的影响。
前瞻性、随机、对照实验。
大学动物实验室和研究单位。
8只雌性比格犬。
在四个时间点测量并计算动脉血压、心率、心输出量、肾血流量、尿量、肌酐清除率和钠排泄分数:a)在输注非诺多泮或生理盐水之前;b)在输注非诺多泮或生理盐水期间(1小时);c)在低血容量期(由急性部分放血诱导)的90分钟内,同时输注非诺多泮或生理盐水;d)在给犬再次输血后的1小时内。
给予非诺多泮(0.1微克/千克/分钟)与血流动力学不稳定无关。在低血容量期,安慰剂组的肾血流量和尿量较基线显著下降(p <.01)(分别从72±20降至47±6毫升/分钟和从0.26±0.15降至0.08±0.05毫升/分钟),而非诺多泮组则无此变化(分别从75±14降至73±17毫升/分钟和从0.3±0.19降至0.14±0.05毫升/分钟)。在低血容量期,安慰剂组的肌酐清除率和钠排泄分数较基线显著下降(p <.01)(分别从3.0±0.4降至1.8±0.8毫升/千克/分钟和从1.7%±0.9%降至0.4%±0.2%),而接受非诺多泮治疗的犬则无此变化(分别从3.0±1.0降至2.9±0.5毫升/千克/分钟和从1.9%±1.1%降至1.7%±2.7%)。
非诺多泮消除了肾小管对严重低血容量的肾前性反应,并维持了肾血流量、肾小球滤过率和利钠作用,且未引起低血压。这表明非诺多泮在急性缺血性损伤中可能具有肾脏保护作用。